Caris Biopharma Partnering
Inform and Empower your Precision Oncology Programs
Have Confidence Caris will Provide You with the Complete Picture
Caris Biopharma leverages leading molecular science and artificial intelligence to help drive the development and commercialization of new therapies.
Precision Biopharma Partnering
Delivering value across the full life cycle of biopharma therapeutics
INFORM with insights from the industry’s most comprehensive clinico-genomic database
- Comprehensive WES & WTS data
- Matched clinico-genomic data (CODEai™)
- Machine learning & Artificial Intelligence
- Expansive tissue and slide repository
EMPOWER through Precision Partnering with customizable offerings
Powering the Future of Precision Medicine with Big Data
By combining molecular science and artificial intelligence with years of experience and a world-leading clinico-genomic database, Caris aims to revolutionize cancer care and deliver on the promise of precision oncology in partnership with biopharma and industry innovators. Our goal is to find the best personalized treatment for every patient. Learn more about how these essential partnerships are powering the future of precision medicine.
Caris Discovery
Identifying novel therapeutic targets in oncology is a critical unmet need. Our proprietary end-to-end discovery platform coupled with deep genomic and matched clinical information will enhance our ability to identify and validate clinically relevant novel targets.
- Robust in-silico and wet lab tools to characterize and validate targets, including proprietary technologies.
- Real-world patient level data to help partners understand the clinical relevance of targets and make early program decisions regarding where to invest and how to optimize.
- Modality agnostic platforms that can be tailored to a specific modality depending on partner needs.
Learn more about Caris’ unparalleled data, innovation lab, and broad footprint to help you unlock otherwise inaccessible target discovery opportunities.
Clinical Development
Caris solutions provide assurance to your development programs by supporting data-driven decisions. Unmatched breadth and depth of profiling coverage from a single platform enables a seamless transition from clinical trial data to real world applications.
- WTS, WES profiling allows you to evolve when science evolves
- RWE projects support decision making
- MI Trials offering accelerates enrollment by identifying biomarker+ patients from our extensive network of clinical sites, with the support of our dedicated oncology nurse navigators
See how Caris solutions can help accelerate development timeline, maximize program potential, and navigate complexities.
Biopharma Commercialization
Enable the future of precision medicine with a platform built to last.
- Co-partnership provides an optimal approach of developing, validating and launching your novel CDx biomarker
- Comprehensive tests and associated services enable the development of multigene signatures and complex biomarkers
- Established Caris commercial reach can seamlessly bridge clinical investigations and global launches
- MI Insights: Biomarker-based alert system for therapeutic commercial success
- Opportunity for coordinated market access and medical education initiatives
Learn how co-partnership provides an optimal approach of developing, validating and launching your novel CDx biomarker.
Dedicated Biopharma Teams for You
Our partners are our priority because we want to help you deliver on the promise of precision oncology
- Diverse experience across biopharma and diagnostic industry
- Expertise in molecular science, clinical development, medical affairs, CDx and commercial
- Thought partnership with our internal experts in medical, bioinformatics, translational medicine, and regulatory
- Passionate and engaged team tailored for each partner
MATCHED CLINICO-GENOMIC PROFILES
RESIDUAL
FFPE
SLIDES
BIOPHARMA PARTNERSHIPS SINCE 2021
PARTNER THERAPUETICS EMPOWERD BY CARIS
Contact Us
"*" indicates required fields